Related stories
Bahrain's National Hotels Reports Q3 Profit of 301,580 Dinars
M impact | EQUITY | Oct 29, 2026, 12:14 PM UTC
aTyr Pharma’s Efzofitimod Misses Primary Endpoint in Phase 3 Trial
aTyr Pharma said efzofitimod missed the primary endpoint in its Phase 3 pulmonary sarcoidosis trial.
M impact | EQUITY | Oct 29, 2026, 12:14 PM UTC
Jordan Industrial Resources Reports Q3 Loss of 24,155 Dinars
M impact | EQUITY | Oct 29, 2026, 12:14 PM UTC
DCN Dx Acquires BioSouthTech to Expand Access to Diverse Patient Populations
DCN Dx acquired the human biospecimen provider BioSouthTech. Its Latin American collection network and banked specimens support broader patient representation.
M impact | EQUITY | Oct 29, 2026, 12:14 PM UTC
Coherus Reports 75% Tagmokitug Response Rate in First-Line ESCC
Coherus Oncology reported a 75% confirmed response rate among evaluable first-line ESCC patients, rising to 89% after the data cutoff. The company plans to expand the cohort.
M impact | EQUITY | Oct 29, 2026, 12:13 PM UTC
Mastercard Publishes Third-Quarter 2026 Earnings Release
Mastercard published its third-quarter 2026 earnings release.
M impact | EQUITY | Oct 29, 2026, 12:12 PM UTC